Psychedelic-assisted therapy is no longer a fringe hypothesis — it is advancing through formal clinical trial infrastructure, and understanding precisely how it produces change matters enormously for translating early signals into durable treatments. This qualitative investigation drills into the psychological mechanisms that may underlie observed improvements in alcohol use disorder, offering a layer of explanation that quantitative trial endpoints alone cannot provide.
Embedded within a Phase 2a open-label trial conducted at two London sites between March 2023 and July 2024, this sub-study used semi-structured interviews to capture reported change processes among ten adults with moderate-to-severe alcohol use disorder who received a single intranasal dose of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT, the compound BPL-003) alongside manualized cognitive behavioral therapy for relapse prevention. Interviews were conducted the day after dosing and again at 12 weeks. Six therapists were also interviewed to triangulate participant accounts. Emerging themes pointed to acute experiential shifts — including altered self-perception, emotional release, and heightened psychological openness — that participants described as facilitating engagement with CBT-based relapse-prevention work in the weeks that followed.
This work sits at a productive intersection of two well-developed traditions: psychedelic pharmacology and evidence-based behavioral therapy. Unlike psilocybin or MDMA, which have accumulated larger trial datasets, 5-MeO-DMT's therapeutic profile is much less characterized, making even preliminary qualitative mapping of its psychological footprint scientifically valuable. The ten-participant sample is too small to support causal claims, and the open-label design introduces expectancy bias that qualitative methods cannot fully resolve. Therapist triangulation adds methodological rigor, but the homogeneity of the sample — predominantly male — limits generalizability. Nevertheless, the study's contribution is conceptual: by naming specific intra-psychic processes rather than merely reporting outcome scores, it generates testable hypotheses for larger confirmatory trials. This is incremental but directionally important work in a rapidly professionalizing field.